13F Holdings
中文EN

KAPA Kairos Pharma, LTD.

Pharmaceutical Preparations · NYSE · SEC CIK 1962011 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-26.3%
TTM EPS YoY83.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-110.8%
ROA-102.8%
ROIC (approx.)-363.5%
Asset turnover—

Leverage & solvency

Liabilities / assets11.3%
Debt / equity0.00x
Current ratio6.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-36.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue———
R&D expense$2.13M$414,000$82,000
SG&A expense$3.44M$1.93M$1.63M
Operating income-$5.57M-$2.34M-$1.71M
Interest expense—$35,000$42,000
Net income-$5.45M-$2.60M-$1.81M
EPS (basic)-0.30-0.23-0.17
EPS (diluted)-0.30-0.23-0.17
Weighted avg. shares (diluted)18.43M11.36M10.38M
Balance sheet
Cash & equivalents$4.49M$1.27M$93,000
Current assets$5.39M$4.17M$101,000
Intangibles$62,000$222,000$382,000
Total assets$6.54M$5.77M$965,000
Current liabilities$199,000$992,000$2.40M
Total liabilities$199,000$992,000$3.04M
Shareholders' equity$6.34M$4.78M-$2.08M
Shares outstanding2.97M13.74M10.56M
Cash flow statement
Operating cash flow-$3.44M-$3.96M$81,000
Financing cash flow$6.66M$5.13M-$425,000

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.